Health TrialsbyHealthPanel

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

ConditionsHidradenitis Suppurativa (HS)Hidradenitis Suppurativa (Acne Inversa)Secukinumab
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 80
SponsorPeking Union Medical College

About this trial

This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS

The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital

Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital

Patients with complete clinical data followed up for at least 1 year

Disqualifiers

Patients lost to follow-up

Patients with less than one year of follow-up

Patients who received additional adjuvant therapy during the follow-up period

Trial population

Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Surgery combined with secukinumab

    Combination product

    Surgery combined with secukinumab

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: Moderate to severe hidradenitis suppurativa1 intervention

Trial outcomes

Primary outcomes

1

HiSCR

at least a 50% reduction in total AN count, with no increase in abscess count, and no increase in draining fistula count relative to baseline)

Time frame
week 52

Secondary outcomes

1

IHS4

the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4)

Time frame
week 52
2

Change in number of inflammatory nodules

Change in number of inflammatory nodules

Time frame
week 52
3

Change in number of abscesses

Change in number of abscesses

Time frame
week 52
4

Change in number of sinus tracts

Change in number of sinus tracts

Time frame
week 52

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking Union Medical College

Lead sponsor

Source ClinicalTrials.gov
Apply now